From: www.ecancer.tv on Fri, Feb 18 2011 8:47 AM

An intravenous infusion of bortezomib is an approved and effective way of treating relapsed multiple myeloma, however there are concerns about the levels of toxicity for this treatment. Prof Philippe Moreau talks about a phase III trial which compared subcutaneous delivery of bortezomib with int...

From: www.ecancer.tv on Fri, Feb 18 2011 8:47 AM

Prof Carlo Gambacorti-Passerini talks about his research into bosutinib as a treatment for patients with Philadelphia chromosome–positive chronic phase chronic myeloid leukaemia. The trial compared bosutinib with imatinib, the current standard therapy for newly diagnosed patients, and patients i...

From: www.ecancer.tv on Mon, Feb 14 2011 7:09 AM

A number of signalling pathways discovered in Drosophila flies and other model organisms have subsequently turned out to be important in cancer and specifically in cancer stem cell function. Prof Mariann Bienz talks about the role of the Wnt signalling pathway in cancer growth and cancer metastas...

From: www.ecancer.tv on Sun, Feb 13 2011 6:14 PM

As the average age of our population increases, the treatment of cancer in the elderly is becoming an increasing concern. Prof Robin Foà explains how patients' suitability for treatments should be decided according to their physiological status as opposed to their age and talks about ecance...

From: www.ecancer.tv on Sun, Feb 13 2011 6:14 PM

Prof Robin Foà speaks about the growing success of the annual European Hematology Association (EHA) congress in recent years and looks forward to the upcoming meeting in London on 9th-12th June 2011. Prof Foà outlines his plans to develop the EHA during his presidency, and discusses some of the ...

From: www.ecancer.tv on Sun, Feb 13 2011 6:14 PM

Prof Bertrand Coiffier speaks about the upcoming meeting on haematological cancers in the elderly, 18-20th March 2011, Rome. Haematological cancers occur most commonly in older patients and this meeting will help clinicians learn how to treat these cancers, something that can be complicated by t...

From: www.ecancer.tv on Sun, Feb 13 2011 6:14 PM

Dr William Wierda speaks about his work developing a treatment for patients with chronic lymphocytic leukaemia (CLL) that are refractory to standard therapies. Patients were divided into those refractory to fludarabine and alemtuzumab and those refractory to fludarabine with bulky lymph nodes, a...

From: www.ecancer.tv on Sun, Feb 13 2011 3:36 PM

Prof Antonio Palumbo talks about ecancer’s upcoming international meeting in Rome, March 18-20th 2010, which will address the treatment of patients over the age of 65 suffering from myeloma, lymphoma, myelodysplasia syndrome, or chronic lymphocytic leukaemia. One of the key issues will be the ov...

From: www.ecancer.tv on Sun, Feb 13 2011 1:08 PM

Prof Sergio Amadori speaks about the upcoming ecancer meeting on blood cancers in elderly patients which will be held in Rome, 18-20th March 2011. Prof Amadori explains how the meeting will help educate clinicians of the issues that must be addressed when treating older cancer patients and the t...

From: www.ecancer.tv on Sun, Feb 13 2011 1:08 PM

Prof Andre Goy talks about his work using inotuzumab ozogamicin and calicheamicin to treat indolent B-cell non-Hodgkin’s lymphoma. The monoclonal antibody inotuzumab ozogamicin was used to deliver calicheamicin, a potent cytotoxic antitumour antibiotic, directly to the surface of tumour cells. P...

From: www.ecancer.tv on Sun, Feb 13 2011 1:08 PM

Prof Lodovico Balducci speaks ecancer’s meeting on blood cancer in elderly patients to be held in Rome, March 18-20th 2011. Haematological cancers occur primarily in older cancer patients and this meeting will help clinicians find out what treatment options are available for older patients suffe...

From: www.ecancer.tv on Sun, Feb 13 2011 1:07 PM

Prof Lodovico Balducci speaks to ecancertv about the Senior Adult Oncology Program he leads at the Moffitt Cancer Center. This programme was established to improve the treatment options available for older cancer patients and to help clinicians recognise that older patients do not necessarily hav...

From: www.ecancer.tv on Tue, Feb 08 2011 9:36 AM

Prof Allan Lipton speaks about three studies comparing the use of denosumab with traditional bisphosphonate based therapy for cancer patients with bone metastases. Denosumab is an antibody which targets a molecule which stimulates oesteoblasts. Patients treated with this drug experienced a lower ...

From: www.ecancer.tv on Tue, Feb 08 2011 9:36 AM

Prof Simon van Belle speaks about the CHOICE study investigating the use of Aranesp (darbepoetin alfa) to treat cancer patients with chemotherapy-induced anaemia. Prof van Belle reports that this drug has successfully increased haemoglobin levels in over 60% of patients, stresses the importance ...

From: www.ecancer.tv on Tue, Feb 08 2011 9:36 AM

Prof Jan Vermorken speaks about the Spectrum study, a phase III trial for patients with recurrent metastatic squamous cell carcinoma of the head and neck. Patients received either cisplatin and 5FU or cisplatin, 5FU and the monoclonal antibody panitumumab. Although this study did not produce a s...

From: www.ecancer.tv on Mon, Feb 07 2011 11:24 AM

Dr Amit Oza, Dr Robert Burger and Prof Nicoletta Colombo participate in a roundtable discussion on the treatment of ovarian cancer. They explain how ovarian cancer is currently treated and talk about results of the ICON7 and GOG-218 clinical trials. These trials have evaluated the use of bevaciz...

From: www.ecancer.tv on Mon, Feb 07 2011 11:23 AM

Dr Caroline Robert and Prof Alexander Eggermont speak about some extremely positive early results, presented at ESMO 2010, of a phase I / II trial of GSK2118436, a new BRAF kinase inhibitor for melanoma patients with brain metastases. Dr Robert and Prof Eggermont discuss this drug, explaining wh...

From: www.ecancer.tv on Wed, Feb 02 2011 12:27 PM

Prof Ignacio Melero speaks about the progress that has been made in the field of tumour immunology. An important part of tumour immunology is the balance between immunity centered genomes which activate the body’s immune response and those that inhibit it. Prof Ignacio Melero talks about potentia...

From: www.ecancer.tv on Wed, Feb 02 2011 8:22 AM

Prof Schrijvers talks to ecancertv at ESMO 2010, Milan, about the importance of palliative care for patients with locally advanced cancer. Patients face various side effects due to toxicities, such as dental problems, osteonecrosis, malnutrition and mucositis. A multidsiciplinary approach and in...

From: www.ecancer.tv on Tue, Feb 01 2011 6:18 AM

Prof Robertson talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about fulvestrant (500mg dose) in comparison to the aromatase inhibitor, anastrozole, when used as a first-line treatment for hormone receptor positive breast cancer. Follow-up data from the FIRST (FASLODEX fIRst l...